APRE MEXC RealStocks
Own real APRE shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-19 05:04:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Aprea Therapeutics, Inc. (APRE) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0.47, with a market capitalization of $5.77M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.39 to $1.49. This page covers its latest market performance, valuation, price trends and company information.
$5.77M | |
$0.44 | |
$0.48 | |
$0.44 | |
$0.45 | |
110.17K | |
352.66K | |
-- | |
$1.49 | |
$0.39 | |
-- | |
2026-09-30 |
Aprea Therapeutics, Inc. (APRE) last closed at $0.47 as of 2026-11-18 23:59:00, up 2.60% ($0.01) from the previous close of $0.45.
During the latest regular trading session, APRE traded between $0.44 and $0.48, with a volume of 110.17K shares. The closing price was near the upper end and near the lower end of its 52-week range.
Over the past seven days, Aprea Therapeutics, Inc. (APRE) moved from $0.50 to $0.47, representing a decline of 6.79% ($0.03).
The stock traded between $0.39 and $0.53 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 363.78 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 7.0%
APRE is currently trading at $0.47, placing it 7.0% of the way from its 52-week low of $0.39 to its 52-week high of $1.49. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 8 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Aprea Therapeutics, Inc. (APRE) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to APRE, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between APRE shares and USD.
APRE Shares to USD
1.00 APRE shares = 0.467 USD
Calculations are estimates based on the latest available price and are for reference only.